Login to Your Account


Gene therapy firm Vivet adds $41M in series A for gene therapy work

By Nuala Moran
Staff Writer

Thursday, May 4, 2017

LONDON – Vivet Therapeutics has raised $41 million in a series A round to fund development of liver-targeted gene therapies for treating inherited metabolic disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics